{
    "items": [
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-strengthens-senior-leadership-with-key-executive-and-board-appointments-alongside-acceleration-of-multiple-t-cell-engager-programs?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-strengthens-senior-leadership-with-key-executive-and-board-appointments-alongside-acceleration-of-multiple-t-cell-engager-programs/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-strengthens-senior-leadership-with-key-executive-and-board-appointments-alongside-acceleration-of-multiple-t-cell-engager-programs/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-strengthens-senior-leadership-with-key-executive-and-board-appointments-alongside-acceleration-of-multiple-t-cell-engager-programs/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-strengthens-senior-leadership-with-key-executive-and-board-appointments-alongside-acceleration-of-multiple-t-cell-engager-programs/responsive_image?ratio=r16x9&amp;scale=w320 320w\"\n             sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-strengthens-senior-leadership-with-key-executive-and-board-appointments-alongside-acceleration-of-multiple-t-cell-engager-programs\" title=\"Enara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen\u00ae and other emerging targets, today announces the appointment of Stacey Davis as Chief Business Officer (CBO) and Chief Financial Officer (CFO). Her appointment strengthens the leadership team at a key moment for Enara as it prepares to transition its lead assets towards clinical development. Stacey most recently served as CBO at Xilio Therapeutics, where she was the architect of a series of major pharma collaborations. In total, Stacey brings over 25 years of experience in delivering growth, innovation, and strategic transformation in the biotech and pharmaceutical industries.\" itemprop=\"name\" class=\"state-published\">Enara Bio strengthens senior leadership with key Executive and Board appointments alongside acceleration of multiple T-Cell engager programs</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">30 April 2025</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Enara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen\u00ae and other emerging targets, today announces the appointment of Stacey Davis as Chief Business Officer (CBO) and Chief Financial Officer (CFO). Her appointment strengthens the leadership team at a key moment for Enara as it prepares to transition its lead assets towards clinical development. Stacey most recently served as CBO at Xilio Therapeutics, where she was the architect of a series of major pharma collaborations. In total, Stacey brings over 25 years of experience in delivering growth, innovation, and strategic transformation in the biotech and pharmaceutical industries.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-appointment-of-two-new-directors-to-its-board?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-appointment-of-two-new-directors-to-its-board/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-appointment-of-two-new-directors-to-its-board/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-appointment-of-two-new-directors-to-its-board/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-appointment-of-two-new-directors-to-its-board/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-appointment-of-two-new-directors-to-its-board\" title=\"PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.\" itemprop=\"name\" class=\"state-published\">PepGen announces appointment of two new directors to its Board</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">30 March 2025</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-named-one-of-times-top-greentech-companies-in-2025?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-named-one-of-times-top-greentech-companies-in-2025/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"MoA Technology logo\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-named-one-of-times-top-greentech-companies-in-2025/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-named-one-of-times-top-greentech-companies-in-2025/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-named-one-of-times-top-greentech-companies-in-2025/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-named-one-of-times-top-greentech-companies-in-2025\" title=\"Moa recognised as leading global innovator in environmental impact.\" itemprop=\"name\" class=\"state-published\">Moa named one of TIME's top greentech companies in 2025</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">26 March 2025</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Moa recognised as leading global innovator in environmental impact.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-technology-forms-new-biological-partnership-with-naicons?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-technology-forms-new-biological-partnership-with-naicons/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-technology-forms-new-biological-partnership-with-naicons/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-technology-forms-new-biological-partnership-with-naicons/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-technology-forms-new-biological-partnership-with-naicons/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-technology-forms-new-biological-partnership-with-naicons\" title=\"Moa and NAICONS join forces to discover the next generation of naturally-occurring herbicides.\" itemprop=\"name\" class=\"state-published\">Moa forms new biological partnership with NAICONS</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">25 March 2025</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Moa and NAICONS join forces to discover the next generation of naturally-occurring herbicides.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-birgitte-volck-as-non-executive-director?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-birgitte-volck-as-non-executive-director/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"A photo of Dr Birgitte Volck\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-birgitte-volck-as-non-executive-director/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-birgitte-volck-as-non-executive-director/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-birgitte-volck-as-non-executive-director/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-birgitte-volck-as-non-executive-director\" title=\"OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Board as a non-executive director.\" itemprop=\"name\" class=\"state-published\">OMass Therapeutics appoints Birgitte Volck as Non-Executive Director</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">26 February 2025</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Board as a non-executive director.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-embarks-on-a-research-collaboration-with-george-washington-university-to-deepen-understanding-of-dark-antigen-r-biology-and-expression?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-embarks-on-a-research-collaboration-with-george-washington-university-to-deepen-understanding-of-dark-antigen-r-biology-and-expression/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\"\n             srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-embarks-on-a-research-collaboration-with-george-washington-university-to-deepen-understanding-of-dark-antigen-r-biology-and-expression/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-embarks-on-a-research-collaboration-with-george-washington-university-to-deepen-understanding-of-dark-antigen-r-biology-and-expression/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-embarks-on-a-research-collaboration-with-george-washington-university-to-deepen-understanding-of-dark-antigen-r-biology-and-expression/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-embarks-on-a-research-collaboration-with-george-washington-university-to-deepen-understanding-of-dark-antigen-r-biology-and-expression\" title=\"Collaboration may inform future combination strategies that can maximise the efficacy of Enara Bio\u2019s pipeline of TCR-based immunotherapies targeting Dark Antigens\u00ae\" itemprop=\"name\" class=\"state-published\">Enara Bio embarks on a research collaboration with George Washington University to deepen understanding of Dark Antigen\u00ae biology and expression</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">18 February 2025</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Collaboration may inform future combination strategies that can maximise the efficacy of Enara Bio\u2019s pipeline of TCR-based immunotherapies targeting Dark Antigens\u00ae</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.thetimes.com/sunday-times-100-tech?ref=image\" title=\"\" target=\"_blank\" rel=\"noopener external\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-listed-in-the-naugural-edition-of-the-sunday-times-100-tech-2025/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"Enara Bio logo\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-listed-in-the-naugural-edition-of-the-sunday-times-100-tech-2025/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-listed-in-the-naugural-edition-of-the-sunday-times-100-tech-2025/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-listed-in-the-naugural-edition-of-the-sunday-times-100-tech-2025/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.thetimes.com/sunday-times-100-tech\" title=\"The guide showcases Britain's fastest-growing private tech companies from The Sunday Times, commercialising innovation across the UK.\r\n\r\n&quot;This recognition is a testament to our innovative science and the hard work of our incredible team as we strive to develop safe and effective treatments for cancer patients.&quot; Enara Bio\" itemprop=\"name\" target=\"_blank\" class=\"state-published\" rel=\"noopener external\">Enara Bio listed in the inaugural edition of The Sunday Times 100 Tech 2025</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">22 January 2025</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">The guide showcases Britain's fastest-growing private tech companies from The Sunday Times, commercialising innovation across the UK.\r\n\r\n\"This recognition is a testament to our innovative science and the hard work of our incredible team as we strive to develop safe and effective treatments for cancer patients.\" Enara Bio</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-enters-into-collaboration-with-lilly-to-discover-research-and-develop-novel-therapies-for-als?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-enters-into-collaboration-with-lilly-to-discover-research-and-develop-novel-therapies-for-als/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"A man in a wheelchair is looking at a tree with lime-green leaves.\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-enters-into-collaboration-with-lilly-to-discover-research-and-develop-novel-therapies-for-als/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-enters-into-collaboration-with-lilly-to-discover-research-and-develop-novel-therapies-for-als/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-enters-into-collaboration-with-lilly-to-discover-research-and-develop-novel-therapies-for-als/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\"\n             itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-enters-into-collaboration-with-lilly-to-discover-research-and-develop-novel-therapies-for-als\" title=\"The agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.\" itemprop=\"name\" class=\"state-published\">Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">9 January 2025</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">The agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-appoints-david-apelian-md-phd-mba-as-ceo?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-appoints-david-apelian-md-phd-mba-as-ceo/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-appoints-david-apelian-md-phd-mba-as-ceo/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-appoints-david-apelian-md-phd-mba-as-ceo/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-appoints-david-apelian-md-phd-mba-as-ceo/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-appoints-david-apelian-md-phd-mba-as-ceo\" title=\"David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer.\" itemprop=\"name\" class=\"state-published\">Theolytics appoints David Apelian MD, PhD, MBA as CEO</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">17 December 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-strengthens-its-leadership-team-with-the-promotions-of-hsin-loke-to-chief-operating-officer-and-jon-roffey-to-senior-vice-president-discovery-and-non-clinical?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-strengthens-its-leadership-team-with-the-promotions-of-hsin-loke-to-chief-operating-officer-and-jon-roffey-to-senior-vice-president-discovery-and-non-clinical/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\"\n             srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-strengthens-its-leadership-team-with-the-promotions-of-hsin-loke-to-chief-operating-officer-and-jon-roffey-to-senior-vice-president-discovery-and-non-clinical/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-strengthens-its-leadership-team-with-the-promotions-of-hsin-loke-to-chief-operating-officer-and-jon-roffey-to-senior-vice-president-discovery-and-non-clinical/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-strengthens-its-leadership-team-with-the-promotions-of-hsin-loke-to-chief-operating-officer-and-jon-roffey-to-senior-vice-president-discovery-and-non-clinical/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-strengthens-its-leadership-team-with-the-promotions-of-hsin-loke-to-chief-operating-officer-and-jon-roffey-to-senior-vice-president-discovery-and-non-clinical\" title=\"OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that the Company has promoted Dr Hsin Loke to Chief Operating Officer (COO) and Jon Roffey Ph.D. to Senior Vice President, Discovery and Non-Clinical, effective immediately.\" itemprop=\"name\" class=\"state-published\">OMass Therapeutics strengthens its leadership team with the promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">6 December 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that the Company has promoted Dr Hsin Loke to Chief Operating Officer (COO) and Jon Roffey Ph.D. to Senior Vice President, Discovery and Non-Clinical, effective immediately.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"A model of the uterus.\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer\" title=\"Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).\" itemprop=\"name\" class=\"state-published\">Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">19 November 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-professor-steven-charlton-as-chief-scientific-officer?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-professor-steven-charlton-as-chief-scientific-officer/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-professor-steven-charlton-as-chief-scientific-officer/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-professor-steven-charlton-as-chief-scientific-officer/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-professor-steven-charlton-as-chief-scientific-officer/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-professor-steven-charlton-as-chief-scientific-officer\" title=\"OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO), effective 1 December 2024. He will take on the role from Dr Ali Jazayeri, who is leaving OMass to pursue other opportunities.\" itemprop=\"name\" class=\"state-published\">OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">15 November 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO), effective 1 December 2024. He will take on the role from Dr Ali Jazayeri, who is leaving OMass to pursue other opportunities.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/cyanocapture-at-the-forefront-h2boost-deployment-and-cosec-horizon-grant-to-scale-biogenic-co2-capture?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/cyanocapture-at-the-forefront-h2boost-deployment-and-cosec-horizon-grant-to-scale-biogenic-co2-capture/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/cyanocapture-at-the-forefront-h2boost-deployment-and-cosec-horizon-grant-to-scale-biogenic-co2-capture/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/cyanocapture-at-the-forefront-h2boost-deployment-and-cosec-horizon-grant-to-scale-biogenic-co2-capture/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/cyanocapture-at-the-forefront-h2boost-deployment-and-cosec-horizon-grant-to-scale-biogenic-co2-capture/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/cyanocapture-at-the-forefront-h2boost-deployment-and-cosec-horizon-grant-to-scale-biogenic-co2-capture\" title=\"CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.\" itemprop=\"name\" class=\"state-published\">CyanoCapture at the forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">10 November 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-announces-a-strategic-collaboration-with-johnson-johnson-to-map-genetic-associations-linked-to-autoimmune-disease?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-announces-a-strategic-collaboration-with-johnson-johnson-to-map-genetic-associations-linked-to-autoimmune-disease/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-announces-a-strategic-collaboration-with-johnson-johnson-to-map-genetic-associations-linked-to-autoimmune-disease/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-announces-a-strategic-collaboration-with-johnson-johnson-to-map-genetic-associations-linked-to-autoimmune-disease/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-announces-a-strategic-collaboration-with-johnson-johnson-to-map-genetic-associations-linked-to-autoimmune-disease/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\"\n             itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-announces-a-strategic-collaboration-with-johnson-johnson-to-map-genetic-associations-linked-to-autoimmune-disease\" title=\"Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson &amp; Johnson*.\" itemprop=\"name\" class=\"state-published\">Nucleome Therapeutics announces a strategic collaboration with Johnson &amp; Johnson to map genetic associations linked to autoimmune disease</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">21 October 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson &amp; Johnson*.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/internationally-renowned-academic-lee-sweetlove-joins-moa?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/internationally-renowned-academic-lee-sweetlove-joins-moa/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"Photo of Lee Sweetlove, Professor of Plant Sciences at the University of Oxford\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/internationally-renowned-academic-lee-sweetlove-joins-moa/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/internationally-renowned-academic-lee-sweetlove-joins-moa/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/internationally-renowned-academic-lee-sweetlove-joins-moa/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/internationally-renowned-academic-lee-sweetlove-joins-moa\" title=\"Moa Technology is pleased to announce that Lee Sweetlove, Professor of Plant Sciences at the University of Oxford, has joined our team. Professor Sweetlove will be working to further understanding of the novel herbicidal modes of action discovered by Moa, which we are currently developing into safe, effective and affordable solutions to protect harvests from crop-killing weeds.\" itemprop=\"name\" class=\"state-published\">Internationally renowned academic Lee Sweetlove joins Moa</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">15 October 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Moa Technology is pleased to announce that Lee Sweetlove, Professor of Plant Sciences at the University of Oxford, has joined our team. Professor Sweetlove will be working to further understanding of the novel herbicidal modes of action discovered by Moa, which we are currently developing into safe, effective and affordable solutions to protect harvests from crop-killing weeds.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa2019s-ground-breaking-science-features-in-journal-weed-science?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa2019s-ground-breaking-science-features-in-journal-weed-science/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa2019s-ground-breaking-science-features-in-journal-weed-science/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/moa2019s-ground-breaking-science-features-in-journal-weed-science/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/moa2019s-ground-breaking-science-features-in-journal-weed-science/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa2019s-ground-breaking-science-features-in-journal-weed-science\" title=\"Breaking the 30 year impasse in novel herbicide discovery.\" itemprop=\"name\" class=\"state-published\">Moa\u2019s groundbreaking science features in journal Weed Science</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">9 October 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Breaking the 30 year impasse in novel herbicide discovery.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel-dark-antigens?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel-dark-antigens/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel-dark-antigens/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel-dark-antigens/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel-dark-antigens/responsive_image?ratio=r16x9&amp;scale=w320 320w\"\n             sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel-dark-antigens\" title=\"Enara Bio today announces the closing of a $32.5M Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, including RA Capital, Samsara BioCapital and SV Health Investors.\" itemprop=\"name\" class=\"state-published\">Enara Bio raises $32.5M Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens\u00ae</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">2 October 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Enara Bio today announces the closing of a $32.5M Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, including RA Capital, Samsara BioCapital and SV Health Investors.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-expands-development-team-with-key-appointments-in-us-and-uk-and-announces-the-nomination-of-clinical-candidate-against-mc2?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-expands-development-team-with-key-appointments-in-us-and-uk-and-announces-the-nomination-of-clinical-candidate-against-mc2/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-expands-development-team-with-key-appointments-in-us-and-uk-and-announces-the-nomination-of-clinical-candidate-against-mc2/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-expands-development-team-with-key-appointments-in-us-and-uk-and-announces-the-nomination-of-clinical-candidate-against-mc2/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-expands-development-team-with-key-appointments-in-us-and-uk-and-announces-the-nomination-of-clinical-candidate-against-mc2/responsive_image?ratio=r16x9&amp;scale=w320 320w\"\n             sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-expands-development-team-with-key-appointments-in-us-and-uk-and-announces-the-nomination-of-clinical-candidate-against-mc2\" title=\"OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the candidate nomination of its lead program targeting the melanocortin-2 (MC2) receptor and key appointments to support its progress towards becoming a clinical-stage company.\" itemprop=\"name\" class=\"state-published\">OMass Therapeutics expands development team with key appointments in US and UK and announces the nomination of clinical candidate against MC2</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">30 September 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the candidate nomination of its lead program targeting the melanocortin-2 (MC2) receptor and key appointments to support its progress towards becoming a clinical-stage company.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-and-biomar-announce-bio-herbicide-collaboration?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-and-biomar-announce-bio-herbicide-collaboration/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-and-biomar-announce-bio-herbicide-collaboration/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-and-biomar-announce-bio-herbicide-collaboration/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-and-biomar-announce-bio-herbicide-collaboration/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-and-biomar-announce-bio-herbicide-collaboration\" title=\"Moa has boosted its bio-herbicide research and development programme with a new long-term collaboration agreement with Biomar Microbial Technologies.\" itemprop=\"name\" class=\"state-published\">Moa and Biomar announce bio-herbicide collaboration</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">16 September 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Moa has boosted its bio-herbicide research and development programme with a new long-term collaboration agreement with Biomar Microbial Technologies.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-news\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n\n        <div class=\"row\">\n\n            \n                <div class=\"col-xs-12 col-sm-4\" style=\"margin-bottom:10px\">\n                    \n\n    <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-appoints-co-founder-jane-osbourn-as-chief-executive-officer?ref=image\" title=\"\">\n        <figure>\n            <div class=\"image-container\">\n                \n\n    \n        \n        <img src=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-appoints-co-founder-jane-osbourn-as-chief-executive-officer/responsive_image?ratio=r16x9&amp;scale=w760\" alt=\"Photo of Jane Osborn\" srcset=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-appoints-co-founder-jane-osbourn-as-chief-executive-officer/responsive_image?ratio=r16x9&amp;scale=w1140 1140w, https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-appoints-co-founder-jane-osbourn-as-chief-executive-officer/responsive_image?ratio=r16x9&amp;scale=w760 760w, https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-appoints-co-founder-jane-osbourn-as-chief-executive-officer/responsive_image?ratio=r16x9&amp;scale=w320 320w\" sizes=\"100vw\" itemprop=\"image\" itemscope=\"\" itemtype=\"http://schema.org/ImageObject\" />\n         \n    \n\n\n            </div>\n            \n        </figure>\n    </a>\n\n\n                </div>\n            \n\n            <div class=\"col-xs-12  col-sm-8\">\n\n                \n\n    <h2 class=\"media-heading\">\n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-appoints-co-founder-jane-osbourn-as-chief-executive-officer\" title=\"Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab\u2019s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as Chief Executive Officer (CEO) and member of the Board.\" itemprop=\"name\" class=\"state-published\">Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer</a>\n    </h2>\n\n\n\n                <p class=\"details\">\n                    \n                        <span itemprop=\"datePublished\">11 September 2024</span>\n                    \n                </p>\n\n                \n                    \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n                \n\n                \n            \n                \n                    <p itemprop=\"description\">Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab\u2019s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as Chief Executive Officer (CEO) and member of the Board.</p>\n                \n\n            </div>\n\n        </div>\n\n    </div>\n\n\n"
    ], 
    "more": "\n\n    \n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/search?category=alumni-news&amp;random=30bd9dec-3a71-451f-8ac8-457491b3f7a6&amp;b_start:int=40&amp;format=json\" title=\"Load more\" class=\"btn btn-default load-more-button\">\n            Load More\n        </a>\n    \n\n", 
    "msg": ""
}